News >

Deferred Treatment Beneficial in Some Patients With MCL

Angelica Welch
Published: Friday, Aug 24, 2018

Jonathon B. Cohen, MD

Jonathon B. Cohen, MD

Mantle cell lymphoma (MCL) is widely described as an aggressive disease for which there is no cure. However, there is a subset of patients with MCL who may benefit from deferred treatment after initial diagnosis, according to Jonathon B. Cohen, MD.

A retrospective analysis was conducted using comprehensive clinical data to evaluate the use of deferred therapy in newly diagnosed patients with MCL. This multicenter cohort analysis also examined safety data associated with patients who were given deferred treatment. Adult patients diagnosed with MCL between 1993 and 2015 from multiple sites were included, comprising a total of 395 patients.

Investigators reported that 72 (18%) patients received deferred therapy; these patients were more likely to have no B symptoms, an ECOG performance status of 0, and normal LDH levels. Deferred therapy did not result in significant changes in overall survival (OS; HR, 0.64; 95% CI, 0.22-1.84; P = .407).

In an interview with OncLive®, Cohen, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discussed the potential benefit of offering deferred therapy to asymptomatic patients with MCL.

OncLive: What was the aim in conducting this analysis?

Cohen: Historically, MCL has been thought to have been an aggressive disease. In the past, the expected survival was only about 3 to 5 years. However, what we have found over the last several years is that there are some patients who present with MCL and have no symptoms and actually a very low burden of disease. In some instances, these are patients who have disease primarily in the bone marrow and the blood, and may not necessarily have a lot of disease in their lymph nodes.

One of the challenges we have had with the management of this disease is that, because it has historically behaved so aggressively, we feel everybody must get aggressive therapy upfront. Then there are these patients with lower-grade disease, clinically, and it just doesn't make sense to treat them so aggressively. Several years ago, there was a study published by the group from Weill Cornell Medicine by Dr Peter Martin, which looked at their own experience in observing patients with MCL who had no symptoms at the time of diagnosis. It appeared that those patients did just as well as patients who were treated right at the time of diagnosis. We did a larger study where we collected data from 5 centers instead of just 1, to try to assess the role of deferred therapy, and to determine whether it is a safe approach for patients with MCL.

What were the findings observed?

We found that a little less than one-fifth of all patients received deferred therapy. The way we defined this was by saying that any patient who did not initiate any sort of chemotherapy within 3 months of their diagnosis was felt to have been deferred. This means that those patients were purposefully not getting treated. Again, we found that in about 18% of patients.

Interestingly, we found that there was no significant impact on OS when we looked at those patients with deferred therapy versus those who received therapy immediately. In fact, it appears that patients who had deferred therapy may live a little bit longer, although it is important to interpret that with caution. This is because those are often patients with lower-risk disease to begin with, and that is how they were ultimately chosen to be deferred. It certainly did not appear to be unsafe; it is a very appropriate option for patients with asymptomatic disease.

What is hindering physicians from offering this as a treatment approach?

There has been some concern over whether it is safe to observe patients with MCL because historically, most patients had more aggressive disease. There have not been a lot of studies to support this type of an approach, so that is why this is important work. Hopefully with these types of findings, it will make physicians feel more comfortable incorporating this as a potential approach to the management of those patients.

What would be your advice for a physician who does not know how to approach the idea of deferred treatment with their patient?

That may be one of the more difficult aspects of the entire process—explaining to a patient the rationale for taking such an approach to management. Certainly, it is unnerving for a patient who has been recently diagnosed with MCL to be told that told they will be observed instead of started on therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication